Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Kaufman, Howard
Item TypeName
Concept Oncolytic Virotherapy
Academic Article Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Academic Article Integrating oncolytic viruses in combination cancer immunotherapy.
Academic Article Oncolytic virus therapy for cancer.
Academic Article Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
Academic Article Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Academic Article Herpes simplex virus oncolytic vaccine therapy in melanoma.
Academic Article Oncolytic viruses: focusing on the tumor microenvironment.
Academic Article Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand.
Academic Article Oncolytic virus immunotherapy for melanoma.
Academic Article Intratumoral Approaches for the Treatment of Melanoma.
Academic Article Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
Academic Article Unleashing the therapeutic potential of oncolytic viruses.
Academic Article Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
Academic Article Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
Academic Article Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.
Academic Article Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
Academic Article Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Academic Article Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Academic Article Two roads for oncolytic immunotherapy development.
Academic Article MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Academic Article Oncolytic Immunotherapy.
Academic Article Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Academic Article Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.
Academic Article An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.
Academic Article Clinical landscape of oncolytic virus research in 2020.
Academic Article Can Surgeons Expand the Role of Oncolytic Viruses for Cancer Treatment? An Editorial Comment on "Fighting Fire with Fire: Oncolytic Virotherapy in Thoracic Malignancies".
Academic Article Advancing oncolytic virus therapy by understanding the biology.
Search Criteria
  • Oncolytic Virotherapy
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.